Overview

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Atridia Pty Ltd.